This article investigates the performance of 2 commercial real-time polymerase chain reaction (PCR) assays, MycAssay™ Aspergillus (MycAspAssay) and MycAssay™ Pneumocystis (MycPCPAssay), on the ABI 7300 platform for the detection of Aspergillus (Asp) or Pneumocystis jirovecii (Pj) DNA in bronchoalveolar lavage (BAL) samples from 20 patients. Operationally, patients enrolled were clustered into 3 groups: invasive aspergillosis group (IA, 7 patients), Pj pneumonia group (PCP, 8 patients), and negative control group (5patients). All the IA patients were MycAspAssay positive, whereas 12 non-IA patients returned negative PCR results. Furthermore, 7 of 8 PCP patients were MycPCPAssay positive, while 9 non-PCP patients were PCR negative. In conclusion, these data provide an early indication of the effectiveness of both the MycAspAssay and MycPCPAssay on the ABI 7300 platform for the detection of either Asp or Pj DNA in BAL from patients with deep fungal infections.
This article investigates the performance of 2 commercial real-time polymerase chain reaction (PCR) assays, MycAssay™ Aspergillus (MycAspAssay) and MycAssay™ Pneumocystis (MycPCPAssay), on the ABI 7300 platform for the detection of Aspergillus (Asp) or Pneumocystis jirovecii (Pj) DNA in bronchoalveolar lavage (BAL) samples from 20 patients. Operationally, patients enrolled were clustered into 3 groups: invasive aspergillosis group (IA, 7 patients), Pj pneumonia group (PCP, 8 patients), and negative control group (5 patients). All the IA patients were MycAspAssay positive, whereas 12 non-IA patients returned negative PCR results. Furthermore, 7 of 8 PCP patients were MycPCPAssay positive, while 9 non-PCP patients were PCR negative. In conclusion, these data provide an early indication of the effectiveness of both the MycAspAssay and MycPCPAssay on the ABI 7300 platform for the detection of either Asp or Pj DNA in BAL from patients with deep fungal infections. © 2012 Elsevier Inc.
Performance of two commercial real-time PCR assays for the detection of Aspergillus and Pneumocystis DNA in bronchoalveolar lavage fluid samples from critical care patients / Orsi, C. F.; Gennari, W.; Venturelli, C.; La Regina, A.; Pecorari, M.; Righi, E.; Machetti, M.; Blasi, E.. - In: DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE. - ISSN 0732-8893. - STAMPA. - 73:2(2012), pp. 138-143. [10.1016/j.diagmicrobio.2012.03.001]
Performance of two commercial real-time PCR assays for the detection of Aspergillus and Pneumocystis DNA in bronchoalveolar lavage fluid samples from critical care patients.
Righi E.;Blasi E.
2012
Abstract
This article investigates the performance of 2 commercial real-time polymerase chain reaction (PCR) assays, MycAssay™ Aspergillus (MycAspAssay) and MycAssay™ Pneumocystis (MycPCPAssay), on the ABI 7300 platform for the detection of Aspergillus (Asp) or Pneumocystis jirovecii (Pj) DNA in bronchoalveolar lavage (BAL) samples from 20 patients. Operationally, patients enrolled were clustered into 3 groups: invasive aspergillosis group (IA, 7 patients), Pj pneumonia group (PCP, 8 patients), and negative control group (5 patients). All the IA patients were MycAspAssay positive, whereas 12 non-IA patients returned negative PCR results. Furthermore, 7 of 8 PCP patients were MycPCPAssay positive, while 9 non-PCP patients were PCR negative. In conclusion, these data provide an early indication of the effectiveness of both the MycAspAssay and MycPCPAssay on the ABI 7300 platform for the detection of either Asp or Pj DNA in BAL from patients with deep fungal infections. © 2012 Elsevier Inc.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
